Societies that value autonomy and harmony tend to have higher alcohol consumption as compared with more conservative societies that value hierarchy and embeddedness, a recent study has shown.
Individuals with alterations in the main driver genes for pancreatic adenocarcinoma have poorer survival outcomes following surgical resection, according to a recent study.
Being diagnosed or treated for gastro-oesophageal reflux disease (GORD) has little impact on the survival outcomes of patients with idiopathic pulmonary fibrosis (IPF), according to a study presented as a poster at APSR 2017.
Results of a study conducted by the Chinese University of Hong Kong (CUHK) revealed that patients who recovered from hepatitis B virus (HBV) infection are still at risk for hepatocellular carcinoma (HCC).
Individuals who have undergone gastrectomy for stomach cancer may have an added risk of developing tuberculosis (TB), according to a study from South Korea. However, this elevated risk does not appear to extend to nontuberculous mycobacteria (NTM) lung disease.
Virtual hepatic venous pressure gradient (vHVPG), a novel noninvasive approach to assess portal hypertension, is shown to correlate well with the gold-standard invasive method in a recent Chinese study.
A recent study from China showed that faecal microbiota transplantation (FMT) is effective as a therapeutic option for patients with inflammatory bowel disease (IBD).
New endoscopic technologies have improved outcomes for patients with upper gastrointestinal bleeding (UGIB), according to Professor James Lau from the Chinese University of Hong Kong, who reviewed current treatment practices and latest advances at the Asian Pacific Digestive Week (APDW) 2017 held recently in Hong Kong.
Sodium phosphate (NaP) tablets for bowel preparation prior to colonoscopy are safe, better tolerated by patients, and provide equivalent and possibly superior colon cleansing compared with standard polyethylene glycol (PEG) solution, a Korean study has found.
Functional cure of hepatitis B virus (HBV) infection could be possible in the near future with the development of drugs that inhibit HBV replication, recent early-phase clinical studies have shown.
Genotypic resistance-guided therapy is no better than traditional empiric therapy for treating patients with refractory Helibacter pylori infection. Researchers found no significant difference in eradication rate between the two strategies when used in the third-line setting.